| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 22.09.2016 og
angivet som gældende fra 20.09.2016 (2887
dage). |
Ingen historik.
| Branche | | Forskning og eksperimentel udvikling indenfor bioteknologi (721100). |
| Sidst opdateret den 09.03.2017 og
angivet som gældende fra 01.01.2017 (2784
dage). |
| Historik | Start | Stop |
|---|
| Forskning og eksperimentel udvikling indenfor bioteknologi (721100) | 01.01.2017 | |
| Uoplyst (999999) | 20.09.2016 | 31.12.2016 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 22.09.2016 og
angivet som gældende fra 20.09.2016 (2887
dage). |
Ingen historik.
| Revisor | | KPMG P/S |
| Sidst opdateret den 09.02.2017 og
angivet som gældende fra 17.01.2017 (2768
dage). |
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Navne | | CiVi Biopharma A/S. |
| Sidst opdateret den 22.09.2016 og
angivet som gældende fra 20.09.2016 (2887
dage). |
Ingen historik.
| Tegningsregel | | Selskabet tegnes af alle bestyrelsesmedlemmer eller af formanden eller næstformanden i forening med den administrerende direktør. |
| Sidst opdateret den 22.09.2016 og
angivet som gældende fra 20.09.2016 (2887
dage). |
| Fortolkning
(3 tegningsmuligheder)
| | alle bestyrelsesmedlemmer |
| formanden + direktøren |
| næstformanden + direktøren |
Ingen historik.
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:KPMG P/S
Revisionsvirksomhedens CVR-nr.:25578198
Beskrivelse af revisor:State Authorized Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):The financial statements are prepared on a going concern basis. The company has discontinued its operations as it døs not have sufficient liquidity to pay its liabilities as they fall due. The Company's Management has had negotiations with its owners and their investors. These negotiations did not lead to any new funding. Therefore, it was decided to file for either solvent liquidation or bankruptcy which was also not disclosed properly in the financial statements. Accordingly, we qualify our opinion to the effect that the financial statements are prepared on a going concern basis.
Furthermore, we have found that the Company has recognized the receivables from group entities with an amount of DKK 1. 750. 000 at year-end. In our view this amount is not recoverable as there is no evidence or indication that the Company will receive any payments on this receivable. Consequently, we deem the receivables from group entities overstated by DKK 1. 750. 000. The write down of these receivables would lead to a loss of DKK 3. 637. 334 for the financial year and an amount of the receivables from group entities with an amount of DKK 0 and an equity of DKK -261. 981 as of 31 December 2023.
We conducted our audit in accordance with International Standard on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.
We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our adverse opinion.
Konklusion (revision):We have audited the financial statements of Company for the financial year 1 January – 31 December 2023, comprising income statement, balance sheet, statement of changes in equity, and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.
In our opinion, because of the significance of the matters described in the "Basis for adverse opinion" section of our report, the financial statements do not give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2023 and of the results of the Company's operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on management's review
Management is responsible for the Management's review.
Our opinion on the financial statements døs not cover the Management's review, and we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.
As disclosed in the "Basis for adverse opinion" section, we have qualified our opinion on the financial statements due to the fact that the financial statements are wrongly prepared on a going concern basis and are missing disclosures regarding the planned liquidation. Furthermore, as also disclosed in the "basis for adverse opinion" section, we found that the financial assets are over materially overstated. We have reached the conclusion that for the same reason, the Management's review is materially misstated in relation to the Company's ability for going.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration